Health Care [ 2/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
It also focuses on pipeline to treat a range of genetic and cardiac diseases.
It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company.
The company was incorporated in 2025 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 26 | -0.97 Decreased by -7.78% | -1.05 Increased by +7.62% |
| Feb 23, 26 | -1.59 Decreased by -98.75% | -1.26 Decreased by -26.19% |
| Nov 10, 25 | -1.27 Decreased by -95.38% | -1.10 Decreased by -15.45% |
| Aug 7, 25 | -1.21 Decreased by -86.15% | -0.96 Decreased by -26.04% |
| May 8, 25 | -0.90 Decreased by -13.92% | -0.88 Decreased by -2.27% |
| Feb 26, 25 | -0.80 Decreased by -1.27% | -0.78 Decreased by -2.45% |
| Nov 7, 24 | -0.65 Increased by +8.45% | -0.72 Increased by +9.72% |
| Aug 9, 24 | -0.65 Increased by +1.52% | -0.78 Increased by +16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 19.64 M Increased by +1.15 K% | -16.63 M Increased by +85.63% | Decreased by -84.71% Increased by +98.85% |
| Dec 31, 25 | 859.00 K Decreased by -71.11% | -48.07 M Increased by +52.99% | Decreased by -5.60 K% Decreased by -62.69% |
| Sep 30, 25 | 12.47 M Increased by +434.03% | -174.44 M Decreased by -116.97% | Decreased by -1.40 K% Increased by +59.37% |
| Jun 30, 25 | 3.85 M Increased by +88.12% | -157.31 M Decreased by -122.22% | Decreased by -4.09 K% Decreased by -18.13% |
| Mar 31, 25 | 1.57 M Decreased by -55.60% | -115.77 M Decreased by -68.14% | Decreased by -7.36 K% Decreased by -278.72% |
| Dec 31, 24 | 2.97 M Increased by +35.57% | -102.26 M Decreased by -69.18% | Decreased by -3.44 K% Decreased by -24.79% |
| Sep 30, 24 | 2.34 M Decreased by -17.10% | -80.40 M Decreased by -53.55% | Decreased by -3.44 K% Decreased by -85.24% |
| Jun 30, 24 | 2.04 M Decreased by -11.70% | -70.79 M Decreased by -50.54% | Decreased by -3.46 K% Decreased by -70.49% |